<DOC>
	<DOC>NCT02271113</DOC>
	<brief_summary>In this study, the investigators will evaluate the safety, pharmacokinetics and effect on target biomarkers of coagulation, cell adhesion, and leukocyte and platelet activation of GMI-1271, an E-selectin antagonist, in healthy volunteers.</brief_summary>
	<brief_title>Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects</brief_title>
	<detailed_description>Investigators will evaluate in a single ascending dose (SAD) and multiple ascending dose (MAD) fashion, the safety, pharmacokinetics and effect on target biomarkers of coagulation, cell adhesion, and leukocyte and platelet activation of GMI-1271, an E-selectin antagonist, in healthy volunteers.</detailed_description>
	<mesh_term>Enoxaparin</mesh_term>
	<criteria>Age 1875 years Male or female Medically healthy, as defined by the absence of clinically significant screening results (e.g. laboratory profile, medical history, electrocardiogram (ECG), physical examination) BMI 1835 kg/m2 Voluntary consent to participate in the study No evidence of Lower Extremity Deep Vein Thrombosis (LE DVT) at baseline by ultrasound Use of any prescription, investigational, herbal, supplemental, or over the counter medications including aspirin within 14 days (for the SAD phase) and 7 days (for the MAD phase) prior to day 1 or unwilling/unable to refrain from the use of these medications on days 18 for the SAD phase and days 112 of the MAD phase of the study Previous administration of GMI1271 Positive drug testing at screening and baseline or positive alcohol testing at baseline or unwilling/unable to refrain from the use of drugs or alcohol on days 18 for the SAD phase and days 112 for the MAD phase of the study Pregnant or breastfeeding Unwilling or unable to use contraception during the time of participation in the trial and 14 days afterwards (sexual abstinence is permissible) Positive HIV, Hepatitis B surface antigen or Hepatitis C antibody at screening Hypersensitivity or allergic reaction to compounds related to GMI1271 Use of moderate caffeine (â‰¥ 300 mg/day) within 48 hours prior to dosing (day 1) History of bleeding disorder Any liver function test &gt; 1.5 times upper limit of normal or renal insufficiency with creatinine clearance &lt; 30 ml/min.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>